Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma

April 22nd 2024

SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma.

Dual Checkpoint Inhibition Leads to Higher Response Rates vs Anti–PD-1 Therapy in High-Risk Resectable Melanoma

April 9th 2024

Ipilimumab plus nivolumab increased response rates vs anti–PD-1 monotherapy, but also increased grade 3 or 4 immune-related adverse effects, in melanoma.

Dr Nathan on Updated Survival Outcomes With Tebentafusp in Metastatic Uveal Melanoma

November 8th 2023

Paul D. Nathan, MBBS, PhD, FRCP, discusses the 3-year survival data from the phase 3 IMCgp100-202 trial of tebentafusp-tebn in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma.

Retrospective Study Shows Nivolumab Associated With OS Benefit After Nivolumab/Ipilimumab irAEs in Advanced Melanoma

November 4th 2023

Elizabeth I. Buchbinder, MD, discusses findings from a retrospective study evaluating the resumption of nivolumab maintenance therapy in patients with advanced melanoma who discontinued treatment with the combination of nivolumab and ipilimumab due to immune-related adverse effects.

mRNA-4157 Plus Pembrolizumab Bolsters RFS in Resected Melanoma

October 23rd 2023

The addition of mRNA-4157 to pembrolizumab led to clinically significant improvements in relapse-free survival and distant metastasis–free survival vs pembrolizumab alone in patients with high-risk resected melanoma.

FDA Approves Adjuvant Nivolumab for Completely Resected Stage IIB/C Melanoma

October 14th 2023

The FDA has approved nivolumab (Opdivo) for the adjuvant treatment of adult and pediatric patients 12 years of age and older with completely resected stage IIB or IIC melanoma.

First-Line UV1 Vaccine Plus Pembrolizumab Sustains OS in Unresectable or Metastatic Melanoma

October 12th 2023

First-line treatment with the universal cancer vaccine UV1 in combination with pembrolizumab sustained overall survival in patients with advanced unresectable or metastatic malignant melanoma, according to updated data from cohort 1 of the phase 1 UV1-103 trial.

Adjuvant Nivolumab Approved in Europe for Completely Resected Stage IIB or IIC Melanoma

August 22nd 2023

The European Commission has approved single-agent nivolumab for use in the adjuvant treatment of adult and adolescent patients aged 12 years or older who have stage IIB or IIC melanoma and who have undergone complete resection.

Pembrolizumab Elicits Long-Term Survival Benefit in Advanced Melanoma

August 17th 2023

Pembrolizumab demonstrated long-term survival benefit compared with ipilimumab in patients with unresectable stage III/IV melanoma who received up to 1 prior systemic therapy.

mRNA-4157 Plus Pembrolizumab Under Further Investigation in Phase 3 Trial in High-Risk Melanoma

July 26th 2023

The combination of mRNA-4157 and pembrolizumab will be further evaluated as an adjuvant treatment option for patients with resected, high-risk, stage IIB to IV melanoma in the phase 3 V940-001 trial.

Adjuvant Nivolumab Receives CHMP Recommendation for Completely Resected Stage IIB/C Melanoma

July 21st 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab monotherapy for the adjuvant treatment of patients at least 12 years of age with completely resected stage IIB or IIC melanoma.

Luke Breaks Down Key Clinical Trial Updates From the 2023 ASCO Annual Meeting

July 17th 2023

Jason Luke, MD, FACP, discusses key takeaways from the KEYNOTE-716 and KEYNOTE-942 trials and other key updates from across the melanoma landscape presented at the 2023 ASCO Annual Meeting.

Adjuvant Pembrolizumab Continues to Provide Survival Benefit in Stage IIB/C Melanoma

June 30th 2023

Pembrolizumab led to sustained improvements in recurrence-free survival and distant metastasis–free survival vs placebo as adjuvant therapy in patients with resected stage IIB or IIC melanoma

Camrelizumab Plus Famitinib Demonstrates Early Antitumor Activity in Advanced Melanoma

June 25th 2023

Camrelizumab combined with famitinib elicited responses and was well tolerated in patients with advanced melanoma previously exposed to an immune checkpoint inhibitor regimen.

Adjuvant mRNA-4157 Plus Pembrolizumab Improves RFS in Resected High-Risk Melanoma

April 16th 2023

mRNA-4157 in combination with pembrolizumab improved recurrence-free survival compared with pembrolizumab alone when used as an adjuvant treatment in patients with resected high-risk melanoma, regardless of tumor mutational burden.

MEDI9253 Plus Durvalumab Delivers Little Efficacy in Advanced/Metastatic Solid Tumors

March 22nd 2023

The addition of MEDI9253 to sequential or concurrent treatment with durvalumab failed to elicit more than 1 partial response although proving feasible and safe in patients with advanced or metastatic solid tumors, according to findings from a phase 1 trial.

Nivolumab Plus Relatlimab Induces Durable Responses in Advanced Melanoma

March 16th 2023

The combination of nivolumab and relatlimab demonstrated clinical benefit with a manageable safety profile in patients with advanced melanoma who have progressed on prior PD-L1 or PD-1 inhibitors, regardless of PD-L1 and LAG-3 expression, according to findings from the ongoing phase 1/2a RELATIVITY-020 trial.

Lifileucel TIL Cell Monotherapy in Patients With Advanced Melanoma After Progression on Immune Checkpoint Inhibitors and Targeted Therapy: Pooled Analysis of Consecutive Cohorts (C-144-01 Study)

February 20th 2023

Amod Sarnaik, MD, reviews data from a study presented at The Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting on lifileucel tumor-infiltrating lymphocyte [TIL] monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapy.

Dr. Pavlick on the Benefit of Neoadjuvant Immunotherapy in Resectable Melanoma

January 16th 2023

Anna C. Pavlick, DO, discusses the potential benefit of neoadjuvant immunotherapy prior to surgical resection, according to results from the phase 2 SWOG S1801 trial.

Neoadjuvant Vidutolimod Plus Nivolumab Demonstrates Favorable Efficacy, Tolerability in Resectable Melanoma

December 5th 2022

The combination of neoadjuvant vidutolimod and nivolumab elicited high response rates and was well tolerated in patients with high-risk, resectable melanoma, according to final results from a phase 2 trial.